Get access to all handy features included in the IVIS website
- Get unlimited access to books, proceedings and journals.
- Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
- Bookmark your favorite articles in My Library for future reading.
- Save future meetings and courses in My Calendar and My e-Learning.
- Ask authors questions and read what others have to say.
Effect of clinical and subclinical mastitis treatment with meloxicam on clinical cure and fertility of dairy cows in Ecuador
Arroba, C.A.; Cerón, J.H.; Rearte...
Get access to all handy features included in the IVIS website
- Get unlimited access to books, proceedings and journals.
- Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
- Bookmark your favorite articles in My Library for future reading.
- Save future meetings and courses in My Calendar and My e-Learning.
- Ask authors questions and read what others have to say.
Read
Objective: To study the effect of clinical and subclinical mastitis treatment with meloxicam on clinical cure rate and fertility of dairy cows in Ecuador.
Material and Methods: Holstein cows from two dairy herds from Pichincha, Ecuador, were used in a study that began in March 2020 and ended in October 2021. Cows with 35-150 days in milk (DIM) had a California Mastitis Test (CMT) done every two weeks and cows with a CMT score 2 (CMT2), score 3 (CMT3), or with clinical mastitis (CM) were enrolled. Cows with odd ear tags were assigned to the control group (CON, n=204), and cows with even tag numbers were assigned to the treatment group (TRT, n=189). Cows with CMT2 in the TRT group were administered meloxicam (0.5 mg/kg BW, Metacam® Boehringer Ingelheim, Ecuador), whereas cows in the CON group remained untreated. Cows with CMT3 and CM in the TRT group were administered an intramammary antibiotic treatment (tetracycline 200mg, neomycin 250 mg, bacitracin 2000 UI, prednisolone 10 mg, Mastijet Fort®, MSD Salud Animal, Mexico) and meloxicam (0.5 mg/kg BW); whereas cows in the CON group were administered the intramammary antibiotic but not the meloxicam treatment. After treatment, cows had a CMT done every two weeks to determine the clinical cure rate (complete, CMT0; partial, CMT reduced; worst, CMT increased or maintained). After a voluntary waiting period of 55 days (d), cows were synchronized with cloprostenol (Ciclase DL®, Zoetis, Ecuador) and AI at detected heat. Cows not detected in heat by 80 DIM were synchronized and timed AI. In addition, for a cow to enroll in the study, the CMT2-3 and CM event had to take place in a window of time of 30 d before 45 d post-AI. Transrectal ultrasonography was used to diagnose pregnancy status at 30±3d post-AI, and those cows diagnosed pregnant were reconfirmed pregnant at 60±3d post-AI. The clinical cure rate (CCR) to CMT2, CMT3+CM at 30 d post-treatment were examined. Pregnancy rate at 30d (PREGR), pregnancy losses at 60 d (PLOSS), calving to conception interval-days open (CCI), number of services per conception (SPC), and culling rate (CULLR) were also analyzed with logistic regression (PROC GLIMMIX, SAS 9.04).
Results: The CCR for CMT3+CM in the TRT group was higher compared to the CON group (72.5% [58/60] vs. 57.3% [43/75], P=0.036), but was similar between CMT2 TRT and CON groups (62.5% [152/243], P=0.73). The PREGR and PLOSS were similar in TRT and CON groups for CMT3+CM (41.9%, P=0.44; 36.76%, P=0.53), and CMT2 (47.22%, P=0.56; 32.35%, P=0.35). The CCI for CMT3+CM in the TRT group was shorter than the CON group (100.66±11.08 vs. 133.23±11.79 d, P=0.04). Also, the SPC for CMT3+CM in the TRT group was lower than the CON group (1.69±0.32 vs. 2.62±0.34, P=0.05). Conversely, the CCI and the SPC were similar between CMT2 TRT and CON groups (118.50±10.95 d, P=0.46; 2.19±0.24, P=0.21). The CULLR was reduced in CMT2 TRT cows compared to CON cows (5.50% [6/109] vs. 15.5% [20/129], P=0.01), but was similar in CMT3+CM TRT and CON cows (14.19% [22/155], P=0.52).
Conclusion: Cows with CMT3+CM that received antibiotic treatment plus meloxicam had a higher clinical cure rate than cows that received antibiotic therapy alone. Furthermore, these cows had fewer days open and lower AI per conception than the untreated cows. In addition, cows with CMT2 had no benefit of meloxicam treatment on clinical cure rate or reproductive performance, but meloxicam treated cows had a lower culling rate during lactation.
Keywords: Clinical mastitis, subclinical mastitis, meloxicam, fertility, clinical cure.
Get access to all handy features included in the IVIS website
- Get unlimited access to books, proceedings and journals.
- Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
- Bookmark your favorite articles in My Library for future reading.
- Save future meetings and courses in My Calendar and My e-Learning.
- Ask authors questions and read what others have to say.
About
Affiliation of the authors at the time of publication
Facultad de Medicina Veterinaria y Zootecnia, Universidad Central de Ecuador, Quito, Ecuador;
Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, Ciudad de México, Mexico;
Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata & CONICET, La Plata, Argentina.
Comments (0)
Ask the author
0 comments